Advertisement

Is the benefit of sodium-glucose cotransporter inhibitors over heart failure progression on the kidney side?

Published:August 16, 2022DOI:https://doi.org/10.1016/j.ejim.2022.08.018
      Dear Editor,

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vallon V.
        • Mü Hlbauer B.E.
        • Osswald H.
        Adenosine and kidney function.
        Physiol Rev. 2006; 86: 901-940
        • Thomson S.C.
        • Vallon V.
        Renal Effects of sodium-glucose co- transporter inhibitors.
        Am J Cardiol. 2019; 124: 28-35https://doi.org/10.1007/s00125-016-4157-3
        • Hansell P.
        • Welch W.J.
        • Blantz R.C.
        Palm F Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension.
        Clin Exp Pharmacol Physiol. 2013; 40: 123-137https://doi.org/10.1111/1440-1681.12034
        • McMurray J.J.V.
        • Solomon S.D.
        • Inzucchi S.E.
        • Køber L.
        • Kosiborod M.N.
        • Martinez F.A.
        • Ponikowski P.
        • Sabatine M.S.
        • Anand I.S.
        • Bělohlávek J.
        • Böhm M.
        • Chiang C.E.
        • Chopra V.K.
        • de Boer R.A.
        • Desai A.S.
        • Diez M.
        • Drozdz J.
        • Dukát A.
        • Ge J.
        • Howlett J.G.
        • Katova T.
        • Kitakaze M.
        • Ljungman C.E.A.
        • Merkely B.
        • Nicolau J.C.
        • O'Meara E.
        • Petrie M.C.
        • Vinh P.N.
        • Schou M.
        • Tereshchenko S.
        • Verma S.
        • Held C.
        • DeMets D.L.
        • Docherty K.F.
        • Jhund P.S.
        • Bengtsson O.
        • Sjöstrand M.
        • Langkilde A.M.
        DAPA-HF Trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008https://doi.org/10.1056/NEJMoa1911303
        • Packer M.
        • Anker S.D.
        • Butler J.
        • Filippatos G.
        • Pocock S.J.
        • Carson P.
        • Januzzi J.
        • Verma S.
        • Tsutsui H.
        • Brueckmann M.
        • Jamal W.
        • Kimura K.
        • Schnee J.
        • Zeller C.
        • Cotton D.
        • Bocchi E.
        • Böhm M.
        • Choi D.J.
        • Chopra V.
        • Chuquiure E.
        • Giannetti N.
        • Janssens S.
        • Zhang J.
        • JR Gonzalez Juanatey
        • Kaul S.
        • HP Brunner-La Rocca
        • Merkely B.
        • Nicholls S.J.
        • Perrone S.
        • Pina I.
        • Ponikowski P.
        • Sattar N.
        • Senni M.
        • Seronde M.F.
        • Spinar J.
        • Squire I.
        • Taddei S.
        • Wanner C.
        • Zannad F
        • EMPEROR-Reduced Trial Investigators
        Cardiovascular and renal outcomes with empagliflozin in heart failure.
        N Engl J Med. 2020; 383: 1413-1424https://doi.org/10.1056/NEJMoa2022190
        • Anker S.D.
        • Butler J.
        • Filippatos G.
        • Ferreira J.P.
        • Bocchi E.
        • Böhm M.
        • Brunner-La Rocca H.P.
        • Choi D.J.
        • Chopra V.
        • Chuquiure-Valenzuela E.
        • Giannetti N.
        • Gomez-Mesa J.E.
        • Janssens S.
        • Januzzi J.L.
        • Gonzalez-Juanatey J.R.
        • Merkely B.
        • Nicholls S.J.
        • Perrone S.V.
        • Piña I.L.
        • Ponikowski P.
        • Senni M.
        • Sim D.
        • Spinar J.
        • Squire I.
        • Taddei S.
        • Tsutsui H.
        • Verma S.
        • Vinereanu D.
        • Zhang J.
        • Carson P.
        • Lam C.S.P.
        • Marx N.
        • Zeller C.
        • Sattar N.
        • Jamal W.
        • Schnaidt S.
        • Schnee J.M.
        • Brueckmann M.
        • Pocock S.J.
        • Zannad F.
        • Packer M.
        EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction.
        N Engl J Med. 2021; 385: 1451-1461https://doi.org/10.1056/NEJMoa2107038
        • Berg D.D.
        • Jhund P.S.
        • Docherty K.F.
        • Murphy S.A.
        • Verma S.
        • Inzucchi S.E.
        • Køber L.
        • Kosiborod M.N.
        • Langkilde A.M.
        • Martinez F.A.
        • Bengtsson O.
        • Ponikowski P.
        • Sjöstrand M.
        • Solomon S.D.
        • McMurray J.J.V.
        • Sabatine M.S.
        Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction.
        JAMA Cardiol. 2021; 6: 499-507https://doi.org/10.1001/jamacardio.2020.7585
        • Jhund P.S.
        • Solomon S.D.
        • Docherty K.F.
        • Heerspink H.J.L.
        • Anand I.S.
        • Böhm M.
        • Chopra V.
        • de Boer R.A.
        • Desai A.S.
        • Ge J.
        • Kitakaze M.
        • Merkley B.
        • O'Meara E.
        • Shou M.
        • Tereshchenko S.
        • Verma S.
        • Vinh P.N.
        • Inzucchi S.E.
        • Køber L.
        • Kosiborod M.N.
        • Martinez F.A.
        • Ponikowski P.
        • Sabatine M.S.
        • Bengtsson O.
        • Langkilde A.M.
        • Sjöstrand M.
        • McMurray J.J.V.
        Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF.
        Circulation. 2021; 143: 298-309https://doi.org/10.1161/CIRCULATIONAHA.120.050391
        • Packer M.
        • Anker S.D.
        • Butler J.
        • Filippatos G.
        • Ferreira J.P.
        • Pocock S.J.
        • et al.
        for the EMPEROR-Reduced Trial Committees and Investigators, Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial, Eur Heart.
        J. 2021; 42: 671-680
        • Petersson M.
        • Friberg P.
        • Eisenhofer G.
        • Lambert G.
        • Rundqvist B.
        Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure.
        Eur Heart J. 2005; 26: 906-913https://doi.org/10.1093/eurheartj/ehi220
        • Khan M.S.
        • Bakris G.L.
        • Packer M.
        • Shahid I.
        • Anker S.D.
        • Fonarow G.C.
        • Wanner C.
        • Weir M.R.
        • Zannad F.
        • Butler J.
        Kidney function assessment and endpoint ascertainment in clinical trials.
        Eur Heart J. 2022; 43: 1379-1400https://doi.org/10.1093/eurheartj/ehab832